Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects
and side effects of thalidomide in radiation-induced brain injury.
Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University /
Yameitang.
Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In
brief, the brain lesion will be evaluated by using brain MRI scan before and after
thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema
volume on FLAIR images at week 15, as compared with that before thalidomide usage.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University